WHO chief Tedros Ghebreyesus today said the trial of hydroxychloroquine for treatment of coronavirus has been suspended over safety concerns. "The authors of Lancet's study reported that among patients receiving hydroxychloroquine, when used alone or with a macrolide, they estimated higher mortality rate," he explained. He added the "safety data" is being reviewed by Data Safety Monitoring Board.WHO chief Tedros Ghebreyesus today said the trial of hydroxychloroquine for treatment of coronavirus has been suspended over safety concerns. “The authors of Lancet’s study reported that among patients receiving hydroxychloroquine, when used alone or with a macrolide, they estimated higher mortality rate,” he explained. He added the “safety data” is being reviewed by Data Safety Monitoring Board.

Leave a Reply

Your email address will not be published. Required fields are marked *